Michael Berk, MD, PhD

MAOI Antidepressants: A History Being Rewritten

November 26, 2025

Members of the International MAOI Expert Group discuss historical use of MAOIs, consider their efficacy and safety, and underscore the importance of reassessing their place in treatment algorithms.

Vincent Van den Eynde, Chittaranjan Andrade, Michael Berk, et al

Original Research

Interpersonal Trauma and Depression Severity in Bipolar Disorder

April 10, 2023

In bipolar disorder patients currently receiving treatment, a history of childhood trauma was associated with more severe depression.

Melvin G. McInnis, Michael Berk, Alyna Turner, et al

Meta-Analysis

N-Acetylcysteine in Depressive Symptoms and Functionality: A Systematic Review and Meta-Analysis

April 27, 2016

Michael Berk, Gin S. Malhi, Seetal Dodd, et al

Original Research

Effects of Asenapine in Bipolar I Patients Meeting Proxy Criteria for Moderate-to-Severe Mixed Major Depressive Episodes: A Post Hoc Analysis

June 24, 2015

Lakshmi N. Yatham, Michael Berk, Gin S. Malhi, et al

Meta-Analysis

Nocebo Effects in the Treatment of Major Depression: Results From an Individual Study Participant-Level Meta-Analysis of the Placebo Arm of Duloxetine Clinical Trials

June 24, 2015

Alexander Schacht, Michael Berk, Gin S. Malhi, et al

Letter to the Editor

Effects of N-Acetyl Cysteine on Suicidal Ideation in Bipolar Depression

May 27, 2015

Michael Berk, Astrid Waterdrinker, Kamalesh Venugopal, et al

Original Research

Efficiency of N-Acetylcysteine in MDD

June 27, 2014

Read about the Efficacy of N-Acetylcysteine in Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Trial.

Michael Berk, Gin S. Malhi, Seetal Dodd, et al

Original Research

Extreme Attributions Predict the Course of Bipolar Depression: Results From the STEP-BD Randomized Controlled Trial of Psychosocial Treatment

March 15, 2013

Andrew A. Nierenberg, Ellen Frank, David J. Miklowitz, et al

Original Research

The Use of Statins After a Cardiac Intervention Is Associated With Reduced Risk of Subsequent Depression: Proof of Concept for the Inflammatory and Oxidative Hypotheses of Depression?

December 14, 2010

Michael Berk, Lesley Stafford

Original Research

Qualitative Methods in Early-Phase Drug Trials: Broadening the Scope of Data and Methods From an RCT of N-Acetylcysteine in Schizophrenia

September 21, 2010

Philippe Conus, Michael Berk, Gin S. Malhi, et al

Original Research

Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Trial With Memantine as Add-On Therapy to Clozapine

October 15, 2009

Michael Berk, David de Lucena, Brisa SimÃµes Fernandes, et al

Original Research

Olanzapine/Fluoxetine Combination for the Treatment of Mixed Depression in Bipolar I Disorder: A Post Hoc Analysis

October 15, 2009

Mark A. Frye, Mauricio Tohen, Franco Benazzi, et al

MAOI Antidepressants: A History Being Rewritten

Interpersonal Trauma and Depression Severity in Bipolar Disorder

N-Acetylcysteine in Depressive Symptoms and Functionality: A Systematic Review and Meta-Analysis

Effects of Asenapine in Bipolar I Patients Meeting Proxy Criteria for Moderate-to-Severe Mixed Major Depressive Episodes: A Post Hoc Analysis

Nocebo Effects in the Treatment of Major Depression: Results From an Individual Study Participant-Level Meta-Analysis of the Placebo Arm of Duloxetine Clinical Trials

Effects of N-Acetyl Cysteine on Suicidal Ideation in Bipolar Depression

Efficiency of N-Acetylcysteine in MDD

Extreme Attributions Predict the Course of Bipolar Depression: Results From the STEP-BD Randomized Controlled Trial of Psychosocial Treatment

The Use of Statins After a Cardiac Intervention Is Associated With Reduced Risk of Subsequent Depression: Proof of Concept for the Inflammatory and Oxidative Hypotheses of Depression?

Qualitative Methods in Early-Phase Drug Trials: Broadening the Scope of Data and Methods From an RCT of N-Acetylcysteine in Schizophrenia

Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Trial With Memantine as Add-On Therapy to Clozapine

Olanzapine/Fluoxetine Combination for the Treatment of Mixed Depression in Bipolar I Disorder: A Post Hoc Analysis

ELSEWHERE:

FOLLOW US:

Michael Berk, MD, PhD

MAOI Antidepressants: A History Being Rewritten

Interpersonal Trauma and Depression Severity in Bipolar Disorder

N-Acetylcysteine in Depressive Symptoms and Functionality: A Systematic Review and Meta-Analysis

Effects of Asenapine in Bipolar I Patients Meeting Proxy Criteria for Moderate-to-Severe Mixed Major Depressive Episodes: A Post Hoc Analysis

Nocebo Effects in the Treatment of Major Depression: Results From an Individual Study Participant-Level Meta-Analysis of the Placebo Arm of Duloxetine Clinical Trials

Effects of N-Acetyl Cysteine on Suicidal Ideation in Bipolar Depression

Efficiency of N-Acetylcysteine in MDD

Extreme Attributions Predict the Course of Bipolar Depression: Results From the STEP-BD Randomized Controlled Trial of Psychosocial Treatment

The Use of Statins After a Cardiac Intervention Is Associated With Reduced Risk of Subsequent Depression: Proof of Concept for the Inflammatory and Oxidative Hypotheses of Depression?

Qualitative Methods in Early-Phase Drug Trials: Broadening the Scope of Data and Methods From an RCT of N-Acetylcysteine in Schizophrenia

Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Trial With Memantine as Add-On Therapy to Clozapine

Olanzapine/Fluoxetine Combination for the Treatment of Mixed Depression in Bipolar I Disorder: A Post Hoc Analysis

Consensus Report on XT Use in Practice

Subscribe to readmore articles

Subscribe to read
more articles